Venetoclax, a selective BCL-2 inhibitor, when combined with hypomethylating agents (e.g., 5-azacytidine) or low-dose cytarabine (LDAC), shows anti-leukemic activity in 60-70% of AML patients [65]. Here, BCL2 is linked to acute myeloid leukemia.